Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has successfully completed the conversion of 25,421,196 domestic shares to H shares, which will be listed on the Hong Kong Stock Exchange. This conversion represents approximately 11.19% of the company’s total share capital, marking a significant step in enhancing the company’s market presence and liquidity in the stock market.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and production of biopharmaceutical products. The company is involved in the biotechnology industry and operates with a market focus on innovative drug development and commercialization.
YTD Price Performance: 88.73%
Average Trading Volume: 616,642
Technical Sentiment Signal: Sell
Current Market Cap: HK$70.04B
For an in-depth examination of 6990 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money